Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

TERN | Terns Pharmaceuticals Inc

IndexRUT P/E- EPS (ttm)-1.29 Insider Own39.22% Shs Outstand53.72M Perf Week-2.71%
Market Cap307.18M Forward P/E- EPS next Y-1.31 Insider Trans0.00% Shs Float37.12M Perf Month-8.21%
Income-72.07M PEG- EPS next Q-0.31 Inst Own65.53% Short Float / Ratio14.30% / 8.36 Perf Quarter-42.51%
Sales0.00M P/S- EPS this Y28.54% Inst Trans28.61% Short Interest5.31M Perf Half Y-57.19%
Book/sh4.49 P/B1.12 EPS next Y-9.99% ROA-33.17% Target Price16.33 Perf Year-10.18%
Cash/sh4.68 P/C1.08 EPS next 5Y- ROE-35.04% 52W Range4.38 - 14.04 Perf YTD-50.59%
Dividend- P/FCF- EPS past 5Y-24.12% ROI-26.27% 52W High-64.18% Beta-0.91
Dividend %- Quick Ratio20.25 Sales past 5Y-25.00% Gross Margin8.70% 52W Low14.84% ATR0.34
Employees46 Current Ratio20.25 Sales Q/Q- Oper. Margin0.00% RSI (14)41.19 Volatility7.22% 5.74%
OptionableYes Debt/Eq0.00 EPS Q/Q54.44% Profit Margin- Rel Volume1.34 Prev Close4.70
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume635.22K Price5.03
Recom1.40 SMA20-3.12% SMA50-15.20% SMA200-44.81% Volume848,347 Change7.02%
Date Action Analyst Rating Change Price Target Change
Jun-22-23Initiated Mizuho Buy $16
Jun-07-23Initiated Jefferies Buy $18
May-31-23Initiated ROTH MKM Buy $23
May-08-23Initiated BMO Capital Markets Outperform $18
Feb-14-23Initiated JMP Securities Mkt Outperform $17
Feb-07-23Initiated UBS Buy $19
Sep-12-22Initiated H.C. Wainwright Neutral $6
Sep-14-21Resumed Goldman Buy $21
Mar-02-21Initiated JP Morgan Overweight $32
Mar-02-21Initiated Goldman Buy $29
Mar-02-21Initiated Cowen Outperform
Sep-06-23 04:05PM
Sep-05-23 04:05PM
Aug-08-23 04:15PM
Aug-03-23 06:00PM
05:05PM Loading…
Jul-28-23 07:01PM
Jul-18-23 04:05PM
Jul-05-23 04:05PM
Jun-26-23 04:05PM
Jun-06-23 04:30PM
Jun-02-23 04:05PM
May-28-23 09:45AM
May-25-23 05:05PM
May-24-23 04:05PM
04:05PM Loading…
May-22-23 04:05PM
May-15-23 08:05AM
May-09-23 04:05PM
May-03-23 04:05PM
Apr-25-23 12:00PM
Mar-30-23 02:28PM
Mar-27-23 04:05PM
Mar-08-23 05:26AM
Mar-02-23 04:05PM
Feb-26-23 10:51AM
Feb-08-23 12:00PM
Feb-02-23 04:05PM
Jan-12-23 04:05PM
Jan-05-23 04:05PM
04:05PM Loading…
Dec-23-22 04:05PM
Dec-20-22 07:40PM
Dec-19-22 04:31PM
Dec-01-22 04:05PM
Nov-16-22 09:31AM
Nov-09-22 04:05PM
Nov-04-22 08:05AM
Oct-26-22 04:05PM
Oct-12-22 05:26AM
Oct-11-22 04:05PM
Sep-29-22 06:03AM
Sep-21-22 05:33AM
Sep-07-22 04:05PM
Aug-19-22 06:50AM
Aug-12-22 08:00AM
Aug-08-22 04:05PM
Jul-27-22 04:05PM
Jul-22-22 12:00PM
Jun-22-22 04:05PM
Jun-09-22 06:31AM
Jun-08-22 04:05PM
Jun-01-22 04:05PM
May-16-22 04:05PM
Apr-05-22 01:38PM
Apr-04-22 04:05PM
Mar-21-22 04:05PM
Mar-03-22 04:05PM
Feb-28-22 04:05PM
Feb-04-22 11:37AM
Feb-02-22 05:38PM
Jan-06-22 07:05AM
Jan-03-22 04:05PM
Nov-15-21 04:05PM
Nov-12-21 07:05AM
Nov-10-21 07:17AM
Nov-09-21 04:05PM
Nov-03-21 02:52PM
Oct-18-21 04:05PM
Oct-05-21 04:05PM
Oct-04-21 08:38AM
Sep-28-21 04:05PM
Sep-15-21 06:07PM
Sep-08-21 07:05AM
Sep-02-21 04:05PM
Aug-16-21 04:05PM
Aug-03-21 04:05PM
Jun-24-21 04:05PM
Jun-14-21 12:41PM
Jun-13-21 05:00PM
May-19-21 05:00PM
May-13-21 04:05PM
May-06-21 08:59AM
Apr-07-21 07:05AM
Mar-30-21 04:05PM
Mar-26-21 07:31AM
Mar-22-21 07:35AM
Mar-08-21 07:00AM
Mar-01-21 03:20PM
Feb-23-21 04:35PM
Feb-14-21 06:01AM
Feb-12-21 10:58AM
Feb-11-21 08:30AM
Feb-10-21 07:05AM
Feb-09-21 09:00AM
Feb-08-21 09:18AM
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lu HongboDirectorDec 23Buy7.25758,6205,499,9954,340,212Dec 23 05:44 PM
Vivo Opportunity, LLC10% OwnerDec 23Buy7.25758,6205,499,9954,340,212Dec 23 05:48 PM
ORBIMED ADVISORS LLCDirectorDec 23Buy7.25137,9311,000,0004,882,854Dec 28 05:57 PM
GORDON CARL LDirectorDec 23Buy7.25137,9311,000,0004,882,854Dec 28 05:46 PM
LAV Biosciences Fund V, L.P.10% OwnerNov 23Sale5.501,500,0008,250,000405,583Nov 28 04:56 PM